Optic Neuritis (ON) is a condition that occurs in approximately 50% of individuals with
relapse remitting MS, and is the presenting event in 15-20% of patients who go on to develop
MS. These ON events present with a decline in vision over several days with painful eye
movements. The purpose of this study is to collect pilot data on the effect of Fampridine-SR
on the recovery of visual function after demyelinating optic neuritis.Our team evaluated a
person with ON who had incomplete recovery which was quite bothersome to her. After a
one-month treatment course Fampridine SR,her visual functioning improved. Based on this case,
we present a unique opportunity to evaluate the potential benefit of Fampridine-SR as a
potential treatment for persons who do not fully recover from acute ON.